REMARKS

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Sequence Listing, file "2006-04-18 1254-0300PUS1.ST25.txt", **is identical to the paper copy**, except that it lacks formatting.

The specification is amended to identify the nucleotide sequences shown in the figures with corresponding SEQ ID NOS. The Sequence Listing is amended to include the sequences from figures 1 and 2 and to properly identify the present application by filing date and serial number. SEQ ID NO: 1 of the Sequence Listing is amended to include the entire 10,939 residues shown in figures 4-1 to 4-3. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

) Roy 747

P.O. Box 747 V

Falls Church, VA 22040-0747

(703) 205-8000

Attachments:

GMM/TJS/psq

1254-0300PUS1

Disk Copy of Sequence Listing Paper Copy of Sequence Listing